Dendrimer News and Research

RSS

RNF41 protein could be a new therapeutic target against cirrhosis and liver inflammation

The RNF41 protein could be a new therapeutic target in the fight against two chronic liver diseases: cirrhosis and liver inflammation.

28 Jul 2023

The safety and preliminary efficacy of OP-101 in patients with severe COVID-19

Researchers assessed the impact of dendrimer nanotherapy in treating severe COVID-19.

8 Aug 2022

Phase 2a clinical trial describes safety and efficacy of dendrimer nanotherapy in severe COVID-19 patients

A multicenter, randomized, placebo-controlled phase 2a clinical trial has recently been conducted to evaluate the efficacy of a nanotherapeutic compound OP-101 in treating severe COVID-19 patients.

21 Jul 2022

Nanotherapeutic compound may help treat inflammation, brain injury in patients with severe COVID-19

An anti-inflammatory compound may have the potential to treat systemic inflammation and brain injury in patients with severe COVID-19 and significantly reduce their chances of death, according to a new study from UTHealth Houston and other institutions.

20 Jul 2022

New method shows how fatty acids are absorbed by single cells

A new method developed by Institute for Systems Biology and University of California, Riverside provides new insights into cancer biology by allowing researchers to show how fatty acids are absorbed by single cells.

16 Jul 2021

Astodrimer sodium exhibits potent virucidal and antiviral activity against SARS-CoV-2 in vitro

Researchers from the US and Australia recently conducted some studies to assess the in vitro antiviral and virucidal (irreversible) activity of astodrimer sodium against SARS-CoV-2.

26 May 2021

The role of nanotechnology in the fight against COVID-19

Appearing in the journal Nanomedicine, the review summarized all the exciting advances made using diverse nanomaterials (polymeric, inorganic self-assembling materials and peptide-based) towards COVID-19 prevention, diagnosis and therapy.

15 Mar 2021

New chemical trap catches trace glycoproteins, shows promise for targeted cancer treatments

Cancer drops sparse chemical hints of its presence early on, but unfortunately, many of them are in a class of biochemicals that could not be detected thoroughly, until now.

8 May 2018

Novel approach could help counter Influenza A virus in immune-compromised patients

To infect its victims, influenza A heads for the lungs, where it latches onto sialic acid on the surface of cells.

24 Oct 2016

New single-agent phototherapy system may form valuable new tool to combat cancer

Researchers at Oregon State University today announced an important advance in the field of cancer imaging and phototherapy, using a single-agent system that may ultimately change the efficacy of cancer surgery and treatment around the world.

30 Oct 2015

Researchers use advanced photodynamic therapy to combat ovarian cancer in laboratory animals

Researchers at Oregon State University have made a significant advance in the use of photodynamic therapy to combat ovarian cancer in laboratory animals, using a combination of techniques that achieved complete cancer cell elimination with no regrowth of tumors.

14 Aug 2015

Dendrimer offers a simple way of creating vesicles

One of the defining features of cells is their membranes. Each cell's repository of DNA and protein-making machinery must be kept stable and secure from invaders and toxins. Scientists have attempted to replicate these properties, but, despite decades of research, even the most basic membrane structures, known as vesicles, still face many problems when made in the lab. They are difficult to make at consistent sizes and lack the stability of their biological counterparts.

11 Jun 2014

Starpharma receives approvals to commence phase 1 human clinical trial for DEP-Docetaxel

Starpharma today announced that it has received the necessary approvals to commence a phase 1 human clinical trial for its dendrimer-enhanced docetaxel (Taxotere®) chemotherapeutic product, referred to as DEP™-Docetaxel.

23 Jan 2014

Research identifies new way for slow release drugs

Reservoirs of pharmaceuticals could be manufactured to bind specifically to infected tissue such as cancer cells for slow, concentrated delivery of drug treatments, according to new research published in ACS Macro Letters.

15 Jan 2014

Nano-devices cross blood-brain barrier to deliver drug to treat cerebral palsy

A team of scientists from Johns Hopkins and elsewhere have developed nano-devices that successfully cross the brain-blood barrier and deliver a drug that tames brain-damaging inflammation in rabbits with cerebral palsy.

23 Apr 2012

Milestone for Starpharma's drug delivery program

Starpharma Holdings today released animal data which demonstrated that its dendrimer-docetaxel formulation applying Starpharma’s dendrimer technology to the leading chemotherapy drug docetaxel was significantly more efficacious than docetaxel (Taxotere®) in a breast cancer model.

1 Feb 2012

Starpharma receives FDA Special Protocol Assessment for bacterial vaginosis phase 3

Starpharma today announced that it has received final written agreement from the FDA on the design of its Phase 3 clinical studies of VivaGel® for the treatment of bacterial vaginosis (BV) under the FDA’s Special Protocol Assessment (SPA) scheme.

10 Jan 2012

Dendrimers offers a new way to treat age-related macular degeneration, retinitis pigmentosa

Hitching a ride into the retina on nanoparticles called dendrimers offers a new way to treat age-related macular degeneration and retinitis pigmentosa. A study by investigators at Mayo Clinic, Wayne State University and Johns Hopkins Medicine shows that steroids attached to the dendrimers target the damage-causing cells associated with neuroinflammation, leaving the rest of the eye unaffected and preserving vision.

14 Dec 2011

Potential nanoparticle treatment for macular degeneration and retinitis pigmentosa

Hitching a ride into the retina on nanoparticles called dendrimers offers a new way to treat age-related macular degeneration and retinitis pigmentosa. A collaborative research study among investigators at Wayne State University, the Mayo Clinic and Johns Hopkins Medicine shows that steroids attached to the dendrimers targeted the damage-causing cells associated with neuroinflammation, leaving the rest of the eye unaffected and preserving vision.